早期乳腺癌同步与序贯放化疗比较:SECRAB III期随机试验
SECRAB是一项在英国48个中心开展的前瞻性、开放标签、多中心III期随机试验,比较早期浸润性乳腺癌同步放化疗与序贯放化疗。共纳入2297例患者(同步组1150例、序贯组1146例),中位随访10.2年。同步组10年局部复发率为4.6%,序贯组为7.1%(HR 0.62;95%CI 0.43-0.90;p=0.012);同步组急性中重度皮肤反应发生率为24%,序贯组为15%(p<0.0001)。
要点
- 同步放化疗较序贯治疗显著降低10年局部复发率(4.6% vs 7.1%,HR 0.62;95%CI 0.43-0.90;p=0.012)。
- 蒽环类-CMF方案亚组中同步治疗获益最明显,10年局部复发率分别为3.5%和6.7%(HR 0.48;95%CI 0.26-0.88;p=0.018)。
- 同步组发生中重度急性皮肤反应的比例更高(24% vs 15%,p<0.0001),但除毛细血管扩张(p=0.03)外远期不良反应没有显著差异。
核心结论
- 同步放化疗较序贯放化疗显著改善早期乳腺癌的局部复发率,且急性毒性增加在可接受范围内。
- 接受蒽环类-CMF方案化疗的患者从同步放化疗中获益最大。
研究设计与样本
- SECRAB为前瞻性、开放标签、多中心、III期随机试验,在英国48个中心开展比较同步与序贯放化疗。
- 1998年7月2日至2004年3月25日共招募2297例患者,同步组1150例、序贯组1146例,采用随机排列区组分配,按中心、腋窝手术、化疗方案和放疗推量进行分层。
主要发现
- 中位随访10.2年,同步组与序贯组的10年局部复发率分别为4.6%和7.1%(HR 0.62;95%CI 0.43-0.90;p=0.012)。
- 蒽环类-CMF方案患者的10年局部复发率分别为3.5%和6.7%(HR 0.48;95%CI 0.26-0.88;p=0.018),同步组获益更明显。
- 两组的总生存和无病生存均无显著差异。
- 同步组24%的患者出现中重度急性皮肤反应,序贯组为15%(p<0.0001);除毛细血管扩张外(p=0.03),两组的远期不良反应无显著差异。
关键数值与推荐
- 同步放疗在CMF方案化疗时安排在第2至第3个周期之间,在蒽环类-CMF方案化疗时安排在第5至第6个周期之间。
- 序贯放疗在化疗完成后进行。
- 放疗方案包括40 Gy/15次,共3周;以及50 Gy/25次,共5周。
- 主要结局指标为5年和10年的局部复发率,按意愿性治疗原则分析。
临床怎么用
- 早期乳腺癌辅助化疗与放疗可考虑同步进行,以降低局部复发风险。
- 采用蒽环类-CMF方案化疗的患者同步放化疗可能获益更大,同时需关注急性皮肤反应的增加。
局限性
- 同步组急性中重度皮肤反应发生率更高(24% vs 15%,p<0.0001)。
- 除毛细血管扩张外(p=0.03),两组的远期不良反应无显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal sequence of adjuvant chemotherapy and radiotherapy for breast cancer is unknown. SECRAB assesses whether local control can be improved without increased toxicity. METHODS: SECRAB was a prospective, open-label, multi-centre, phase III trial comparing synchronous to sequential chemo-radiotherapy, conducted in 48 UK centres. Patients with invasive, early stage breast cancer were eligible. Randomisation (performed using random permuted block assignment) was stratified by centre, axillary surgery, chemotherapy, and radiotherapy boost. Permitted chemotherapy regimens included CMF and anthracycline-CMF. Synchronous radiotherapy was administered between cycles two and three for CMF or five and six for anthracycline-CMF. Sequential radiotherapy was delivered on chemotherapy completion. Radiotherapy schedules included 40 Gy/15F over three weeks, and 50 Gy/25F over five weeks. The primary outcome was local recurrence at five and ten years, defined as time to local recurrence, and analysed by intention to treat. ClinicalTrials.gov NCT00003893. FINDINGS: Between 02-July-1998 and 25-March-2004, 2297 patients were recruited (1150 synchronous and 1146 sequential). Baseline characteristics were balanced. With 10.2 years median follow-up, the ten-year local recurrence rates were 4.6% and 7.1% in the synchronous and sequential arms respectively (hazard ratio (HR) 0.62; 95% confidence interval (CI): 0.43-0.90; p = 0.012). In a planned sub-group analysis of anthracycline-CMF, the ten-year local recurrence rates difference were 3.5% versus 6.7% respectively (HR 0.48 95% CI: 0.26-0.88; p = 0.018). There was no significant difference in overall or disease-free survival. 24% of patients on the synchronous arm suffered moderate/severe acute skin reactions compared to 15% on the sequential arm (p < 0.0001). There were no significant differences in late adverse effects apart from telangiectasia (p = 0.03). INTERPRETATION: Synchronous chemo-radiotherapy significantly improved local recurrence rates. This was delivered with an acceptable increase in acute toxicity. The greatest benefit of synchronous chemo-radiation was in patients treated with anthracycline-CMF. FUNDING: Cancer Research UK (CR UK/98/001) and Pharmacia.
引用
- Fernando IN, Bowden SJ, Herring K, et al. Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial. Radiother Oncol. 2019. PMID: 31785830. doi:10.1016/j.radonc.2019.10.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。